Enveric Biosciences, Inc.
ENVB
$1.27
$0.010.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.88% | 225.50% | -40.61% | -60.35% | -36.04% |
| Depreciation & Amortization | -5.15% | -2.60% | -1.74% | -1.97% | -1.27% |
| Other Operating Expenses | -- | -129.57% | -- | -- | -- |
| Total Operating Expenses | -11.70% | 33.11% | -39.59% | -67.02% | -49.03% |
| Operating Income | 11.70% | -33.11% | 39.59% | 67.02% | 49.03% |
| Income Before Tax | 11.01% | 7.80% | 25.98% | 70.43% | 47.51% |
| Income Tax Expenses | -- | -67.71% | -- | -- | -- |
| Earnings from Continuing Operations | 11.07% | 8.19% | 26.16% | 70.43% | 47.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.07% | 8.19% | 26.16% | 70.43% | 47.47% |
| EBIT | 11.70% | -33.11% | 39.59% | 67.02% | 49.03% |
| EBITDA | 11.93% | -34.42% | 40.56% | 68.01% | 49.90% |
| EPS Basic | 86.80% | 78.73% | 81.63% | 91.84% | 73.42% |
| Normalized Basic EPS | 86.79% | 78.64% | 81.59% | 91.79% | 72.74% |
| EPS Diluted | 86.80% | 78.73% | 81.63% | 91.84% | 73.42% |
| Normalized Diluted EPS | 86.79% | 78.64% | 81.59% | 91.79% | 72.74% |
| Average Basic Shares Outstanding | 573.84% | 331.65% | 302.08% | 260.07% | 92.50% |
| Average Diluted Shares Outstanding | 573.84% | 331.65% | 302.08% | 260.07% | 92.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |